Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy of Once-daily Dosing of IMM-124E (Travelan®) in a Controlled Human Infection Model for Enterotoxigenic Escherichia Coli (ETEC)

NCT05933525 is registered in ClinicalTrials.gov with Immuron Ltd. as lead sponsor.

NCT NCT05933525
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05933525 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy of Once-daily Dosing of IMM-124E (Travelan®) in a Controlled Human Infection Model for Enterotoxigenic Escherichia Coli (ETEC)
Lead sponsor
Immuron Ltd.
Phase
Phase 2
Overall status
Completed
Start date
May 29, 2023
Completion date
December 30, 2024
Enrollment
63 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diarrhea, infectious diarrhea, travelers diarrhea